HCVD2MAG-67K

MILLIPLEX^® Human Cardiovascular Disease Panel

Name: MILLIPLEX<SUP>®</SUP> Human Cardiovascular Disease Panel
Brand: MM

Configurable Human CVD 10-Plex Panel 2

别名:

CVD assay snapshot, CVD multiplex product sheet, cardiovascular biomarker listing, cardiovascular biomarker profile, coagulation and inflammation detection kit, human CVD assay overview, human cardiovascular panel summary, human cardiovascular research tool, human vascular biomarker info, vascular inflammation biomarker panel

登录查看组织和合同定价。

关于此项目

UNSPSC Code:

12161503

NACRES:

NA.84

eCl@ss:

32161000

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

产品名称

MILLIPLEX^® Human Cardiovascular Disease Panel, Configurable Human CVD 10-Plex Panel 2

species reactivity

human

manufacturer/tradename

Milliplex^®

Quality Level

200

packaging

1 ea of

assay range

accuracy: 88%
(Myoglobin)
accuracy: 90%
(P-selectin)
accuracy: 98%
(GDF-15)
standard curve range: 0.0005-2.5 ng/mL
(GDF-15)
standard curve range: 0.012-50 ng/mL
(Lipocalcin-2/NGAL)
standard curve range: 0.024-100 ng/mL
(Myoglobin & MPO)
standard curve range: 0.085-350 ng/mL
(sICAM-1)
standard curve range: 0.122-500 ng/mL
(sVCAM-1)
standard curve range: 0.244-1,000 ng/mL
(D-dimer, SAA & P-selectin)
standard curve range: 1.221-5,000 ng/mL
(ADAMTS 13)
inter-assay cv: <20%
intra-assay cv: <15%

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

detection method

fluorometric (Luminex^® xMAP^® technology)

shipped in

wet ice

storage temp.

2-8°C

Biochem/physiol Actions

Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

Features:

Targets biomarkers involved in vascular inflammation, endothelial activation, and coagulation
Includes 10 analytes relevant to cardiovascular risk, oxidative stress, and immune response
Multiplex format enables simultaneous detection from minimal sample volume
Compatible with human serum and plasma samples
Designed for research in atherosclerosis, thrombosis, acute coronary syndromes, and systemic inflammation

Benefits:

Provides a comprehensive profile of cardiovascular and inflammatory biomarkers
Supports investigation of vascular injury, immune activation, and thrombotic mechanisms
Facilitates evaluation of therapeutic interventions and biomarker-based risk assessment
Enables high-throughput analysis with reduced sample and reagent use
Delivers reproducible, sensitive results for translational and clinical research

General description

Cardiovascular disease is closely linked to inflammation, endothelial dysfunction, oxidative stress, and coagulation abnormalities. This set of biomarkers—ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, and sVCAM-1—captures key indicators of vascular injury, immune activation, and thrombotic risk. These analytes are widely studied in the context of atherosclerosis, acute coronary syndromes, and systemic inflammation, making them highly relevant for translational and clinical cardiovascular research.

Application

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 10 analytes in human serum, plasma, or cell culture supernatants.

Analytes included: ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, sVCAM-1Note: D-Dimer cannot be measured in plasma samples.

Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.

pictograms

GHS07,GHS09

signalword

Warning

hcodes

H302 + H312 + H332,H315,H317,H319,H335,H411

pcodes

P273 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

存储类别

10 - Combustible liquids

wgk

WGK 3

法规信息

新产品

此项目有

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Patterns of circulating inflammatory biomarkers in older persons with varying levels of physical performance: a partial least squares-discriminant analysis approach.

Emanuele Marzetti et al.

Frontiers in medicine, 1, 27-27 (2015-01-17)

Chronic, low-grade inflammation and declining physical function are hallmarks of the aging process. However, previous attempts to correlate individual inflammatory biomarkers with physical performance in older people have produced mixed results. Given the complexity of the inflammatory response, the simultaneous

Systemic inflammation, body composition, and physical performance in old community-dwellers.

Riccardo Calvani et al.

Journal of cachexia, sarcopenia and muscle, 8(1), 69-77 (2016-11-30)

Chronic inflammation, changes in body composition, and declining physical function are hallmarks of the ageing process. The aim of the present study was to provide a preliminary characterisation of the relationship among these age-related phenomena via multivariate modelling. Thirty-five old

Evaluation of inflammatory biomarkers, carotid intima-media thickness and cardiovascular risk in HIV-1 treatment-naive patients.

Priscila Valéria do Carmo Carvalho et al.

Revista da Sociedade Brasileira de Medicina Tropical, 51(3), 277-283 (2018-07-05)

Mortality among HIV patients is 3-15 times higher than that among the general population. Currently, most deaths are due to non-infectious diseases. Chronic inflammation and adverse events due to antiretroviral therapy play crucial roles in increasing cardiovascular risk (CVR). This

The influence of sleep apnea syndrome and intermittent hypoxia in carotid adventitial vasa vasorum.

Carolina López-Cano et al.

PloS one, 14(2), e0211742-e0211742 (2019-02-06)

Subjects with sleep apnea-hypopnea syndrome (SAHS) show an increased carotid intima-media thickness. However, no data exist about earlier markers of atheromatous disease, such as the proliferation and expansion of the adventitial vasa vasorum (VV) to the avascular intima in this

Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis.

Sigurdardottir, G; Ekman, AK; St?hle, M; Bivik, C; Enerback, C

Journal of the American Academy of Dermatology null

查看所有相关文献

MILLIPLEX® Human Cardiovascular Disease Panel